Michelle Hoaitrang Nguyen, MD
Gastroenterology · Los Gatos
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 30
- 7 carriers
- Office
- 1
On the public record
- Owns National Ambulatory Surgery Center, LLC.: Accreditation Revoked
Offices
1 location · Genesis Healthcare Partners PC · 232 clinicians in this group
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
30 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office at (408) 345-5925 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A74533 · Current
Licensed to practise in California · since 2001 · expires 2027-01-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- National Ambulatory Surgery Center, LLC.Ambulatory Surgery Center · Los Angeles, CA22% owner since 2024 · accredited by AAAHCAccreditation Revoked2 inspections, 1 with deficiencies · last 2025-07-30
- National Ambulatory Surgery Center LLCAmbulatory Surgery Center · Los Angeles, CA16.4% owner since 2025 · accredited by AAAASFInitial Accreditation1 inspection, 1 with deficiencies · last 2025-10-07
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$111,569
Medicare paid this office $111,569 for 288 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 55 | $29,181 | $45 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 56 | $21,510 | $58 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 60 | $14,226 | $237 |
| Return visit (30+ min) | 45 | $5,983 | $115 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 52 | $5,330 | $103 |
See all 15 services
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 55 | $29,181 | $45 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 56 | $21,510 | $58 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 60 | $14,226 | $237 |
| Return visit (30+ min) | 45 | $5,983 | $115 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 52 | $5,330 | $103 |
| Biopsy of large bowel using a flexible endoscope | 38 | $5,133 | $135 |
| New patient visit (45+ min) | 39 | $4,936 | $127 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 12 | $4,857 | $53 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 12 | $3,944 | $48 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,285 | $205 |
| Short return visit (20+ min) | 30 | $2,701 | $82 |
| New patient visit (30+ min) | 15 | $1,492 | $99 |
| Short return visit | 24 | $1,342 | $54 |
| New patient visit (15+ min) | 22 | $1,173 | $53 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $179 | $15 |
Procedures Medicare counted
| Colonoscopy | 53 | More than 65% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 31 | More than 56% of doctors who do this |
Who their Medicare patients are
288 Original Medicare patients in 2024. Average age 73 · Women 78% · Also on Medicaid 10% · Health risk score 0.84. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 68% · Diabetes 28% · Coronary heart disease 26% · Cancer 18% · Depression 17% · Atrial fibrillation 13% · Chronic kidney disease 10% · COPD 10% · Heart failure 8% · Stroke 7%.
The office billed $607,620, Medicare allowed $142,595 and paid $111,569; for 1,620 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 288 | 1,620 | 73 | 0.84 | $607,620 | $111,569 |
| 2023 | 333 | 1,428 | 73 | 0.94 | $557,726 | $105,894 |
| 2022 | 395 | 1,740 | 73 | 0.98 | $488,730 | $132,948 |
| 2021 | 403 | 1,291 | 73 | 0.97 | $349,851 | $120,114 |
| 2020 | 286 | 743 | 73 | 1.12 | $244,701 | $76,744 |
| 2019 | 221 | 707 | 74 | 1.09 | $180,013 | $70,159 |
| 2018 | 174 | 564 | 74 | 0.90 | $370,977 | $40,553 |
| 2017 | 242 | 683 | 74 | 0.94 | $448,759 | $54,106 |
| 2016 | 301 | 578 | 74 | 0.96 | $594,460 | $75,395 |
| 2015 | 257 | 484 | 74 | 0.97 | $499,241 | $76,374 |
| 2014 | 249 | 441 | 73 | 0.89 | $452,809 | $68,000 |
| 2013 | 201 | 377 | 72 | 1.07 | $389,945 | $59,988 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 52 | $22,260 | $44 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 52 | $16,861 | $56 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 50 | $11,898 | $238 |
| New patient visit (45+ min) | 57 | $8,214 | $144 |
| Return visit (30+ min) | 57 | $7,503 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $6,534 | $98 |
| Biopsy of large bowel using a flexible endoscope | 35 | $5,073 | $145 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 12 | $3,722 | $55 |
| Short return visit (20+ min) | 45 | $3,565 | $77 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 17 | $3,504 | $206 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,094 | $206 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 11 | $2,820 | $48 |
| New patient visit (60+ min) | 11 | $2,104 | $191 |
| Short return visit | 34 | $1,882 | $52 |
| New patient visit (15+ min) | 33 | $1,839 | $56 |
| New patient visit (30+ min) | 15 | $1,470 | $98 |
2022: 15 services
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 44 | $24,181 | $45 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 44 | $18,063 | $58 |
| Short return visit (20+ min) | 164 | $16,307 | $76 |
| Return visit (30+ min) | 98 | $12,311 | $107 |
| New patient visit (45+ min) | 93 | $10,998 | $118 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 45 | $10,410 | $231 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 79 | $7,625 | $97 |
| Biopsy of large bowel using a flexible endoscope | 50 | $7,128 | $143 |
| New patient visit (30+ min) | 46 | $4,036 | $88 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,039 | $203 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 12 | $2,514 | $209 |
| New patient visit (60+ min) | 11 | $2,291 | $208 |
| New patient visit (15+ min) | 28 | $1,530 | $55 |
| Short return visit | 20 | $1,032 | $49 |
| Measurement of liver stiffness | 12 | $362 | $28 |
2021: 16 services
| New patient visit (45+ min) | 156 | $22,533 | $144 |
| Return visit (30+ min) | 119 | $20,553 | $115 |
| Short return visit (20+ min) | 116 | $11,428 | $83 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 49 | $11,321 | $231 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 81 | $8,153 | $99 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 27 | $7,730 | $36 |
| Biopsy of large bowel using a flexible endoscope | 59 | $7,393 | $125 |
| New patient visit (60+ min) | 25 | $5,295 | $212 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 27 | $5,188 | $39 |
| New patient visit (30+ min) | 42 | $3,555 | $85 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,106 | $207 |
| Long return visit (40+ min) | 11 | $2,095 | $175 |
| Short return visit | 39 | $2,088 | $52 |
| New patient visit (15+ min) | 20 | $1,007 | $50 |
| Measurement of liver stiffness | 19 | $579 | $28 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 11 | $117 | $10 |
2020: 12 services
| Return visit (30+ min) | 109 | $16,372 | $99 |
| New patient visit (45+ min) | 110 | $15,493 | $141 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $11,965 | $235 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | $4,917 | $102 |
| Biopsy of large bowel using a flexible endoscope | 42 | $4,131 | $98 |
| Short return visit (20+ min) | 50 | $4,050 | $71 |
| New patient visit (30+ min) | 38 | $3,273 | $86 |
| New patient visit (60+ min) | 19 | $2,820 | $148 |
| Short return visit | 27 | $1,302 | $42 |
| New patient visit (15+ min) | 18 | $930 | $52 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 72 | $340 | $5 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 17 | $145 | $9 |
2019: 13 services
| New patient visit (45+ min) | 109 | $15,518 | $142 |
| Return visit (30+ min) | 77 | $13,146 | $101 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 36 | $8,386 | $233 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 63 | $6,728 | $104 |
| Biopsy of large bowel using a flexible endoscope | 43 | $5,320 | $124 |
| New patient visit (30+ min) | 42 | $3,496 | $83 |
| New patient visit (60+ min) | 16 | $2,670 | $167 |
| Long return visit (40+ min) | 16 | $2,505 | $139 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,374 | $216 |
| Short return visit (20+ min) | 25 | $1,999 | $69 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,334 | $121 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 101 | $494 | $5 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 16 | $152 | $9 |
2018: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 50 | $11,630 | $233 |
| Biopsy of large bowel using a flexible endoscope | 49 | $3,984 | $81 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 19 | $3,982 | $210 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,782 | $93 |
| Long return visit (40+ min) | 23 | $2,729 | $109 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 106 | $2,107 | $12 |
| New patient visit (45+ min) | 11 | $1,478 | $134 |
| Return visit (30+ min) | 16 | $1,428 | $89 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 120 | $587 | $5 |
2017: 15 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 59 | $13,592 | $230 |
| Long return visit (40+ min) | 48 | $7,942 | $119 |
| Biopsy of large bowel using a flexible endoscope | 49 | $3,989 | $81 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 17 | $3,606 | $212 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $3,250 | $98 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,167 | $211 |
| New patient visit (45+ min) | 16 | $2,002 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,984 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,880 | $171 |
| Return visit (30+ min) | 21 | $1,713 | $78 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 88 | $1,390 | $10 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,383 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $947 | $63 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 114 | $477 | $4 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 29 | $305 | $10 |
2016: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 82 | $18,859 | $230 |
| Long return visit (40+ min) | 63 | $10,249 | $119 |
| Biopsy of large bowel using a flexible endoscope | 84 | $7,841 | $93 |
| New patient visit (45+ min) | 45 | $6,255 | $139 |
| Diagnostic exam of large bowel using a flexible endoscope | 33 | $5,068 | $154 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 54 | $4,911 | $91 |
| Return visit (30+ min) | 41 | $4,897 | $96 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,534 | $96 |
| Injection beneath lining of large bowel using a flexible endoscope | 17 | $613 | $36 |
2015: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 68 | $19,639 | $285 |
| Long return visit (40+ min) | 57 | $9,227 | $134 |
| Biopsy of large bowel using a flexible endoscope | 49 | $6,499 | $130 |
| New patient visit (60+ min) | 32 | $6,263 | $196 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 60 | $6,135 | $101 |
| New patient visit (45+ min) | 31 | $4,708 | $152 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,888 | $243 |
| Return visit (30+ min) | 28 | $3,011 | $100 |
| Injection beneath lining of large bowel using a flexible endoscope | 15 | $406 | $27 |
2014: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 57 | $15,162 | $266 |
| Long return visit (40+ min) | 44 | $10,190 | $129 |
| Biopsy of large bowel using a flexible endoscope | 51 | $6,231 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 44 | $4,759 | $103 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 19 | $4,576 | $241 |
| New patient visit (45+ min) | 30 | $4,308 | $144 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 15 | $3,613 | $241 |
| Return visit (30+ min) | 20 | $2,098 | $91 |
| New patient visit (30+ min) | 18 | $1,701 | $95 |
2013: 10 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 49 | $13,257 | $271 |
| Long return visit (40+ min) | 37 | $7,213 | $127 |
| Biopsy of large bowel using a flexible endoscope | 32 | $5,236 | $164 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 22 | $5,045 | $229 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 31 | $3,556 | $115 |
| Return visit (30+ min) | 22 | $2,212 | $88 |
| New patient visit (45+ min) | 15 | $2,105 | $140 |
| New patient visit (30+ min) | 14 | $1,411 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $936 | $62 |
| Injection beneath lining of large bowel using a flexible endoscope | 20 | $727 | $36 |
Medicaid work
$0 in 2022
Medicaid paid $0 for 55 billed services this clinician did in 2022, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 40 | $0 |
| Return visit (30+ min) | 15 | $0 |
| 2022 | 55 | 2 | 14 | $0 |
| 2021 | 41 | 2 | 16 | $0 |
| 2020 | 53 | 2 | 14 | $186 |
See the largest Medicaid services in earlier years
2021
| Short return visit (20+ min) | 13 | $0 |
| Return visit (30+ min) | 28 | $0 |
2020
| New patient visit (45+ min) | 13 | $145 |
| Return visit (30+ min) | 40 | $41 |
Drugs they prescribed that Part D paid
$440,676
Pharmacies billed $440,676 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
457 generic and 167 brand-name prescriptions · $440,676 in drug cost · 45 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 32 | $172,272 | $5,383 |
| Zenpep | 22 | $104,253 | $4,739 |
| Xifaxan | 11 | $25,262 | $2,297 |
| Motegrity | 12 | $18,989 | $1,582 |
| Linzess | 11 | $12,246 | $1,113 |
See all 16 drugs
| Creon | 32 | $172,272 | $5,383 |
| Zenpep | 22 | $104,253 | $4,739 |
| Xifaxan | 11 | $25,262 | $2,297 |
| Motegrity | 12 | $18,989 | $1,582 |
| Linzess | 11 | $12,246 | $1,113 |
| Sutab | 16 | $2,608 | $163 |
| Plenvu | 14 | $2,026 | $145 |
| Pantoprazole | 95 | $1,479 | $16 |
| Colestipol | 14 | $1,115 | $80 |
| Cholestyramine | 20 | $1,110 | $56 |
| Famotidine | 83 | $973 | $12 |
| Sod Sulf-Potass Sulf-Mag Sulf | 13 | $785 | $60 |
| Omeprazole | 46 | $444 | $10 |
| Ondansetron Odt | 18 | $436 | $24 |
| Sucralfate | 11 | $277 | $25 |
| Promethazine | 13 | $183 | $14 |
Year by year
| 2024 | 624 | 208 | None | 27% | $440,676 |
| 2023 | 853 | 294 | None | None | $513,035 |
| 2022 | 1,085 | 336 | 0% (0) | None | $511,032 |
| 2021 | 1,290 | 357 | None | None | $404,062 |
| 2020 | 946 | 283 | None | None | $307,296 |
| 2019 | 656 | 214 | 0% (0) | 36% | $310,107 |
| 2018 | 461 | 180 | 3% (12) | 26% | $80,737 |
| 2017 | 575 | 232 | None | None | $74,449 |
| 2016 | 678 | 291 | None | 32% | $65,194 |
| 2015 | 528 | 209 | None | None | $63,643 |
| 2014 | 381 | 177 | None | None | $45,860 |
| 2013 | 419 | 191 | None | 38% | $45,788 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Creon | 41 | $227,778 | $5,556 |
| Zenpep | 18 | $63,999 | $3,556 |
| Xifaxan | 26 | $57,274 | $2,203 |
| Linzess | 26 | $28,828 | $1,109 |
| Ozempic | 13 | $25,013 | $1,924 |
| Motegrity | 15 | $16,871 | $1,125 |
| Sutab | 28 | $4,624 | $165 |
| Cholestyramine | 37 | $4,422 | $120 |
| Ursodiol | 11 | $3,295 | $300 |
| Pantoprazole | 122 | $2,198 | $18 |
| Famotidine | 102 | $2,101 | $21 |
| Sod Sulf-Potass Sulf-Mag Sulf | 25 | $1,954 | $78 |
| Omeprazole | 64 | $1,068 | $17 |
| Lactulose | 21 | $927 | $44 |
| Sucralfate | 16 | $635 | $40 |
| Hydrocortisone | 12 | $461 | $38 |
| Diphenoxylate-Atropine | 15 | $378 | $25 |
| Neomycin Sulfate | 12 | $315 | $26 |
2022: 23 drugs
| Creon | 45 | $221,230 | $4,916 |
| Xifaxan | 23 | $53,354 | $2,320 |
| Linzess | 41 | $36,748 | $896 |
| Motegrity | 22 | $18,172 | $826 |
| Vemlidy | 13 | $16,409 | $1,262 |
| Mesalamine | 23 | $15,595 | $678 |
| Cholestyramine | 58 | $6,568 | $113 |
| Prevalite | 32 | $4,240 | $133 |
| Suprep | 37 | $4,224 | $114 |
| Sutab | 23 | $3,683 | $160 |
| Ursodiol | 19 | $3,589 | $189 |
| Pantoprazole | 155 | $3,098 | $20 |
| Famotidine | 107 | $2,166 | $20 |
| Budesonide Ec | 15 | $2,026 | $135 |
| Lactulose | 25 | $1,201 | $48 |
| Sucralfate | 24 | $1,184 | $49 |
| Cholestyramine Light | 11 | $1,015 | $92 |
| Proctozone-Hc | 11 | $908 | $83 |
| Omeprazole | 55 | $859 | $16 |
| Cyproheptadine | 23 | $549 | $24 |
| Dicyclomine | 15 | $447 | $30 |
| Baclofen | 15 | $161 | $11 |
| Metoclopramide | 17 | $93 | $5 |
2021: 29 drugs
| Xifaxan | 44 | $97,736 | $2,221 |
| Creon | 18 | $66,499 | $3,694 |
| Linzess | 54 | $47,022 | $871 |
| Vemlidy | 18 | $22,154 | $1,231 |
| Mesalamine | 17 | $20,485 | $1,205 |
| Dexilant | 22 | $11,951 | $543 |
| Suprep | 63 | $6,953 | $110 |
| Cholestyramine | 45 | $5,416 | $120 |
| Prevalite | 28 | $3,986 | $142 |
| Cholestyramine Light | 25 | $3,916 | $157 |
| Sutab | 25 | $3,820 | $153 |
| Pantoprazole | 179 | $3,320 | $19 |
| Budesonide Dr | 15 | $3,111 | $207 |
| Famotidine | 68 | $1,928 | $28 |
| Lactulose | 27 | $1,445 | $54 |
| Sucralfate | 23 | $1,395 | $61 |
| Dicyclomine | 38 | $1,230 | $32 |
| Omeprazole | 101 | $1,208 | $12 |
| Esomeprazole Magnesium | 15 | $1,090 | $73 |
| Constulose | 13 | $867 | $67 |
| Ondansetron | 18 | $690 | $38 |
| Neomycin Sulfate | 28 | $676 | $24 |
| Diphenoxylate-Atropine | 14 | $600 | $43 |
| Cyproheptadine | 17 | $473 | $28 |
| Baclofen | 26 | $310 | $12 |
| Lidocaine Hcl Viscous | 13 | $242 | $19 |
| Amoxicillin-Clavulanate Potass | 20 | $179 | $9 |
| Metronidazole | 16 | $178 | $11 |
| Metoclopramide | 15 | $138 | $9 |
2020: 24 drugs
| Xifaxan | 35 | $73,540 | $2,101 |
| Creon | 12 | $52,252 | $4,354 |
| Linzess | 54 | $31,611 | $585 |
| Vemlidy | 16 | $18,929 | $1,183 |
| Dexilant | 27 | $12,455 | $461 |
| Suprep | 79 | $8,226 | $104 |
| Cholestyramine | 50 | $6,231 | $125 |
| Clenpiq | 18 | $2,573 | $143 |
| Sucralfate | 21 | $1,990 | $95 |
| Budesonide Ec | 11 | $1,893 | $172 |
| Cholestyramine Light | 14 | $1,818 | $130 |
| Esomeprazole Magnesium | 15 | $1,730 | $115 |
| Pantoprazole | 124 | $1,526 | $12 |
| Omeprazole | 66 | $972 | $15 |
| Famotidine | 28 | $709 | $25 |
| Diphenoxylate-Atropine | 18 | $543 | $30 |
| Lidocaine Hcl Viscous | 25 | $506 | $20 |
| Dicyclomine | 20 | $504 | $25 |
| Cyproheptadine | 11 | $315 | $29 |
| Neomycin Sulfate | 12 | $275 | $23 |
| Baclofen | 14 | $258 | $18 |
| Metoclopramide | 19 | $203 | $11 |
| Metronidazole | 16 | $198 | $12 |
| Gavilyte-G | 11 | $153 | $14 |
2019: 19 drugs
| Xifaxan | 14 | $22,351 | $1,597 |
| Linzess | 29 | $18,372 | $634 |
| Baraclude | 11 | $15,260 | $1,387 |
| Dexilant | 23 | $12,136 | $528 |
| Zenpep | 13 | $10,331 | $795 |
| Suprep | 54 | $5,317 | $98 |
| Cholestyramine | 20 | $2,229 | $111 |
| Sucralfate | 43 | $1,807 | $42 |
| Clenpiq | 12 | $1,699 | $142 |
| Pantoprazole | 64 | $1,109 | $17 |
| Omeprazole | 48 | $861 | $18 |
| Lactulose | 14 | $778 | $56 |
| Proctozone-Hc | 13 | $500 | $38 |
| Metronidazole | 26 | $385 | $15 |
| Dicyclomine | 19 | $284 | $15 |
| Gavilyte-G | 19 | $267 | $14 |
| Ranitidine | 11 | $237 | $22 |
| Ondansetron | 11 | $199 | $18 |
| Famotidine | 12 | $193 | $16 |
2018: 11 drugs
| Dexilant | 15 | $5,846 | $390 |
| Tenofovir Disoproxil | 13 | $3,563 | $274 |
| Cholestyramine | 18 | $3,353 | $186 |
| Balsalazide Disodium | 12 | $2,027 | $169 |
| Pantoprazole | 53 | $888 | $17 |
| Peg 3350-Electrolyte | 52 | $817 | $16 |
| Ranitidine | 37 | $773 | $21 |
| Gavilyte-N | 37 | $703 | $19 |
| Sucralfate | 15 | $493 | $33 |
| Omeprazole | 38 | $377 | $10 |
| Famotidine | 16 | $220 | $14 |
2017: 9 drugs
| Linzess | 19 | $15,385 | $810 |
| Cholestyramine | 17 | $3,683 | $217 |
| Pantoprazole | 108 | $1,336 | $12 |
| Peg 3350-Electrolyte | 74 | $1,026 | $14 |
| Ranitidine | 49 | $930 | $19 |
| Omeprazole | 50 | $895 | $18 |
| Diphenoxylate-Atropine | 11 | $881 | $80 |
| Famotidine | 30 | $602 | $20 |
| Gavilyte-N | 32 | $554 | $17 |
2016: 11 drugs
| Linzess | 18 | $11,809 | $656 |
| Dexilant | 14 | $4,273 | $305 |
| Cholestyramine | 23 | $3,165 | $138 |
| Peg 3350-Electrolyte | 102 | $1,597 | $16 |
| Omeprazole | 72 | $1,415 | $20 |
| Diphenoxylate-Atropine | 23 | $1,115 | $48 |
| Suprep | 13 | $1,071 | $82 |
| Pantoprazole | 102 | $1,055 | $10 |
| Ranitidine | 49 | $780 | $16 |
| Gavilyte-N | 39 | $703 | $18 |
| Famotidine | 22 | $360 | $16 |
2015: 14 drugs
| Nexium | 21 | $11,089 | $528 |
| Dexilant | 20 | $7,524 | $376 |
| Ursodiol | 13 | $6,822 | $525 |
| Linzess | 14 | $6,166 | $440 |
| Cholestyramine | 38 | $4,418 | $116 |
| Omeprazole | 69 | $1,206 | $17 |
| Peg 3350-Electrolyte | 66 | $1,186 | $18 |
| Pantoprazole | 64 | $779 | $12 |
| Polyethylene Glycol 3350 | 18 | $501 | $28 |
| Gavilyte-N | 23 | $445 | $19 |
| Diphenoxylate-Atropine | 12 | $402 | $33 |
| Lidocaine Hcl Viscous | 12 | $291 | $24 |
| Famotidine | 15 | $233 | $16 |
| Ranitidine | 12 | $143 | $12 |
2014: 10 drugs
| Nexium | 12 | $8,115 | $676 |
| Dexilant | 14 | $6,228 | $445 |
| Ursodiol | 19 | $3,589 | $189 |
| Pantoprazole | 68 | $1,163 | $17 |
| Peg-3350 | 52 | $953 | $18 |
| Moviprep | 12 | $952 | $79 |
| Omeprazole | 37 | $713 | $19 |
| Gavilyte-N | 24 | $480 | $20 |
| Famotidine | 16 | $414 | $26 |
| Polyethylene Glycol 3350 | 12 | $322 | $27 |
2013: 8 drugs
| Dexilant | 21 | $5,471 | $261 |
| Pantoprazole | 91 | $1,903 | $21 |
| Omeprazole | 36 | $1,212 | $34 |
| Moviprep | 16 | $1,134 | $71 |
| Sucralfate | 21 | $807 | $38 |
| Peg-3350 With Flavor Packs | 43 | $806 | $19 |
| Gavilyte-N | 22 | $392 | $18 |
| Trilyte With Flavor Packets | 12 | $208 | $17 |
Money from drug and device companies
$8,391 in 2025
| 2025 | 13 | 86 | $6,650 | $8,391 |
| 2024 | 16 | 95 | $6,650 | $8,448 |
| 2023 | 20 | 91 | $5,300 | $6,835 |
| 2022 | 8 | 75 | $4,050 | $5,036 |
| 2021 | 12 | 109 | $31,909 | $33,391 |
| 2020 | 11 | 49 | $40,730 | $41,850 |
| 2019 | 5 | 9 | None | $303 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Linzess | $7,378 | 42 payments
|
| Gilead Sciences | None | $185 | 11 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $182 | 5 payments
|
| Janssen Biotech | Tremfya | $155 | 7 payments
|
| Aimmune Therapeutics | Zenpep | $120 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $91 | 4 payments
|
See all 86 published payments
| Janssen Biotech | Meals · 2025-12-16 | Tremfya | $25 |
| Gilead Sciences | Meals · 2025-12-11 | None | $19 |
| Aimmune Therapeutics | Meals · 2025-12-04 | Zenpep | $31 |
| Ardelyx | Meals · 2025-12-03 | Ibsrela | $22 |
| Abbvie | Paid to speak or teach · 2025-11-26 | Linzess | $1,425 |
| Gilead Sciences | Meals · 2025-11-20 | None | $8 |
| Celltrion USA | Meals · 2025-11-18 | Vegzelma | $20 |
| Aimmune Therapeutics | Meals · 2025-11-17 | Zenpep | $20 |
| Abbvie | Paid to speak or teach · 2025-11-13 | Linzess | $1,425 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-11 | Xifaxan | $121 |
| Abbvie | Meals · 2025-11-06 | Creon | $8 |
| Ardelyx | Meals · 2025-11-06 | Ibsrela | $17 |
| Abbvie | Meals · 2025-10-30 | Creon | $25 |
| Abbvie | Meals · 2025-10-30 | Creon | $25 |
| Abbvie | Meals · 2025-10-22 | Creon | $9 |
| Abbvie | Meals · 2025-10-22 | Creon | $9 |
| Abbvie | Meals · 2025-10-21 | Skyrizi | $24 |
| Abbvie | Meals · 2025-10-15 | Viberzi | $26 |
| Abbvie | Meals · 2025-10-15 | Viberzi | $26 |
| Abbvie | Paid to speak or teach · 2025-09-25 | None | $2,375 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-22 | Xifaxan | $11 |
| Abbvie | Meals · 2025-09-16 | Rinvoq | $28 |
| Gilead Sciences | Meals · 2025-09-11 | None | $18 |
| Abbvie | Meals · 2025-09-10 | Linzess | $26 |
| Abbvie | Meals · 2025-09-10 | Linzess | $26 |
| Abbvie | Meals · 2025-09-05 | None | $100 |
| Abbvie | Meals · 2025-08-28 | Viberzi | $25 |
| Genzyme | Meals · 2025-08-27 | Dupixent | $44 |
| Abbvie | Meals · 2025-08-08 | Linzess | $20 |
| Abbvie | Meals · 2025-08-08 | Linzess | $20 |
| Abbvie | Meals · 2025-07-31 | Viberzi | $6 |
| Abbvie | Meals · 2025-07-31 | Viberzi | $6 |
| Celltrion USA | Meals · 2025-07-31 | Vegzelma | $24 |
| Abbvie | Meals · 2025-07-18 | Creon | $2 |
| Abbvie | Meals · 2025-07-18 | Creon | $2 |
| Abbvie | Meals · 2025-07-18 | Creon | $20 |
| Abbvie | Meals · 2025-07-18 | Creon | $20 |
| Abbvie | Meals · 2025-07-17 | Linzess | $14 |
| Abbvie | Meals · 2025-07-17 | Linzess | $14 |
| Gilead Sciences | Meals · 2025-07-17 | None | $28 |
| Abbvie | Meals · 2025-07-14 | Rinvoq | $24 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-07-09 | Xifaxan | $23 |
| Aimmune Therapeutics | Meals · 2025-07-02 | Zenpep | $32 |
| Gilead Sciences | Meals · 2025-06-25 | None | $32 |
| Gilead Sciences | Meals · 2025-06-19 | None | $26 |
| Ardelyx | Meals · 2025-06-18 | Ibsrela | $16 |
| Abbvie | Paid to speak or teach · 2025-06-16 | Creon | $1,425 |
| Abbvie | Meals · 2025-06-13 | Linzess | $15 |
| Janssen Biotech | Meals · 2025-06-10 | Tremfya | $19 |
| Abbvie | Meals · 2025-06-06 | Linzess | $7 |
| Abbvie | Meals · 2025-06-06 | Linzess | $7 |
| Abbvie | Meals · 2025-06-05 | Linzess | $1 |
| Abbvie | Meals · 2025-06-05 | Linzess | $1 |
| Aimmune Therapeutics | Meals · 2025-06-05 | Zenpep | $14 |
| Celltrion USA | Meals · 2025-06-05 | Vegzelma | $16 |
| Fresenius Kabi USA | Meals · 2025-05-29 | None | $35 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-27 | Xifaxan | $13 |
| Aimmune Therapeutics | Meals · 2025-05-14 | Zenpep | $23 |
| Vivus | Meals · 2025-05-06 | Pancreaze | $24 |
| Abbvie | Meals · 2025-05-05 | Rinvoq | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-01 | Entyvio | $19 |
| Gilead Sciences | Meals · 2025-05-01 | None | $8 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $20 |
| Janssen Biotech | Meals · 2025-04-24 | Tremfya | $34 |
| Abbvie | Meals · 2025-04-24 | Creon | $19 |
| Gilead Sciences | Meals · 2025-04-24 | None | $8 |
| Abbvie | Meals · 2025-04-17 | Linzess | $22 |
| Gilead Sciences | Meals · 2025-04-17 | None | $8 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Entyvio | $27 |
| Celltrion USA | Meals · 2025-04-08 | Vegzelma | $19 |
| Abbvie | Meals · 2025-03-20 | Viberzi | $27 |
| Abbvie | Meals · 2025-03-20 | Viberzi | $27 |
| Abbvie | Meals · 2025-03-12 | Rinvoq | $26 |
| Pfizer | Meals · 2025-03-12 | Xeljanz | $20 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-06 | Xifaxan | $15 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-05 | Entyvio | $22 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $6 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-13 | Entyvio | $22 |
| Abbvie | Meals · 2025-02-06 | Linzess | $15 |
| Janssen Biotech | Meals · 2025-01-28 | Tremfya | $25 |
| Abbvie | Meals · 2025-01-27 | Linzess | $7 |
| Gilead Sciences | Meals · 2025-01-22 | None | $23 |
| Gilead Sciences | Meals · 2025-01-08 | None | $8 |
| Madrigal Pharmaceuticals | Meals · 2025-01-08 | Rezdiffra | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $8,448
| Abbvie | Creon | $7,410 | 37 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $295 | 25 payments
|
| Janssen Biotech | Tremfya | $149 | 7 payments
|
| Pfizer | Xeljanz | $125 | 5 payments
|
| Celltrion USA | Vegzelma | $74 | 3 payments
|
| Ironwood Pharmaceuticals | Linzess | $71 | 4 payments
|
| Gilead Sciences | None | $55 | 2 payments
|
| Lilly USA | Omvoh | $41 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $38 | 2 payments
|
| Vertos Medical | Mild Device Kit | $38 | 1 payment
|
| Biotissue Holdings | None | $36 | 1 payment
|
| Braintree Laboratories | Suflave | $31 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $29 | 1 payment
|
| Ipsen Biopharmaceuticals | Iqirvo | $22 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $18 | 1 payment
|
| QOL Medical | Sucraid | $17 | 1 payment
|
2023: $6,835
| Abbvie | Linzess | $4,588 | 42 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $1,342 | 8 payments
|
| Celgene | Zeposia | $186 | 14 payments
|
| Gilead Sciences | Vemlidy | $166 | 5 payments
|
| Intercept Pharmaceuticals | Ocaliva | $80 | 3 payments
|
| Ardelyx | Ibsrela | $68 | 2 payments
|
| Aimmune Therapeutics | Vowst | $64 | 2 payments
|
| Nestle Healthcare Nutrition | Vowst | $50 | 2 payments
|
| Novo Nordisk | Wegovy | $47 | 2 payments
|
| Celltrion USA | Yuflyma | $29 | 1 payment
|
| Genzyme | Dupixent | $26 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $25 | 1 payment
|
| Astellas Pharma US | None | $25 | 1 payment
|
| Vivus | Pancreaze | $24 | 1 payment
|
| Braintree Laboratories | Suflave | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $19 | 1 payment
|
| Micro-tech Endoscopy USA | Lockado | $18 | 1 payment
|
| Lilly USA | None | $18 | 1 payment
|
| Merck Sharp & Dohme | None | $15 | 1 payment
|
2022: $5,036
| Abbvie | Creon | $4,550 | 43 payments
|
| Janssen Biotech | Stelara | $153 | 8 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $149 | 16 payments
|
| Merck Sharp & Dohme | Dificid | $64 | 3 payments
|
| Nestle HealthCare Nutrition | Zenpep | $51 | 2 payments
|
| Ardelyx | Ibsrela | $28 | 1 payment
|
| Gilead Sciences | None | $25 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $15 | 1 payment
|
2021: $33,391
| CapsoVision | Capsocam Colon | $28,309 | 3 payments
|
| AbbVie | Creon | $3,203 | 35 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $1,444 | 43 payments
|
| Nestle HealthCare Nutrition | Zenpep | $204 | 17 payments
|
| RedHill Biopharma | Talicia | $58 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $32 | 1 payment
|
| Gilead Sciences | None | $31 | 2 payments
|
| Alfasigma USA | Zelnorm | $29 | 1 payment
|
| Braintree Laboratories | Sutab | $25 | 1 payment
|
| Pfizer | Xeljanz | $25 | 1 payment
|
| Daiichi Sankyo | Injectafer | $19 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $14 | 1 payment
|
2020: $41,850
| CapsoVision | None | $38,500 | 5 payments
|
| Gilead Sciences | Vemlidy | $2,515 | 7 payments
|
| AbbVie | Humira | $457 | 24 payments
|
| Eisai | Lenvima | $125 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Motegrity | $63 | 2 payments
|
| Coloplast | Continence Care | $44 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $39 | 2 payments
|
| Nestle HealthCare Nutrition | Zenpep | $36 | 2 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $34 | 2 payments
|
| Ferring Pharmaceuticals | Cimzia | $25 | 1 payment
|
| RedHill Biopharma | Talicia | $13 | 1 payment
|
2019: $303
| Amarin Pharma | Vascepa | $143 | 1 payment
|
| AbbVie | Mavyret | $81 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $38 | 2 payments
|
| Braintree Laboratories | Motofen | $27 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
Checkups this office reported
2 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Patients can see their records onlinePatients who were given electronic access to their health information | 95%That's most of the people this applied to. | 483 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 98%That's most of the people this applied to. | 876 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Chronic Care and Preventative Care Management for Empaneled Patients
- Did a security review of patient data
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Implementation of formal quality improvement methods, practice changes, or other practice improvement processes
- Implementation of medication management practice improvements
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports to a public-health or clinical registry
- Use of QCDR data for ongoing practice assessment and improvements
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1811967920
- Licence
- CA A74533California A74533: Current · expires 2027-01-31
- Trained
- University of Michigan Medical School, 1998
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 1010 N Central Ave, Ste 380, Glendale, CA, 91202
- NPI first listed
- 2006-01-23
- NPI last updated
- 2018-10-22
This is when the NPI record was last certified, not a medical board exam.